David A. Siegel Aquestive Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 551,700 shares of AQST stock, worth $3.88 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

551,700

Previous 576,400 4.29%

Holding current value

$3.88 Million

Previous $1.67 Million 9.28%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$2.22 - $3.58 $54,834 - $88,426	-24,700 Reduced 4.29%	551,700 $1.83 Million
Q1 2025 May 15, 2025	BUY	$2.54 - $3.75 $1.42 Million - $2.1 Million	560,400 Added 3502.5%	576,400 $1.67 Million
Q4 2024 Feb 14, 2025	BUY	$3.46 - $5.64 $55,360 - $90,240	16,000 New	16,000 $56,000
Q2 2024 Aug 14, 2024	BUY	$2.31 - $4.5 $21,714 - $42,300	9,400 Added 63.51%	24,200 $62,000
Q1 2024 May 15, 2024	SELL	$2.01 - $6.09 $24,119 - $73,080	-12,000 Reduced 44.78%	14,800 $63,000
Q4 2023 Feb 14, 2024	SELL	$1.29 - $2.47 $4,257 - $8,151	-3,300 Reduced 10.96%	26,800 $54,000
Q3 2023 Nov 14, 2023	BUY	$1.5 - $2.24 $2,550 - $3,808	1,700 Added 5.99%	30,100 $46,000
Q2 2023 Aug 14, 2023	BUY	$1.06 - $2.49 $5,618 - $13,197	5,300 Added 22.94%	28,400 $46,000
Q1 2023 May 15, 2023	SELL	$0.72 - $1.15 $6,696 - $10,695	-9,300 Reduced 28.7%	23,100 $26,000
Q4 2022 Feb 14, 2023	SELL	$0.77 - $1.18 $5,775 - $8,850	-7,500 Reduced 18.8%	32,400 $29,000
Q3 2022 Nov 14, 2022	SELL	$0.63 - $1.73 $5,040 - $13,840	-8,000 Reduced 16.7%	39,900 $47,000
Q2 2022 Aug 15, 2022	SELL	$0.64 - $2.57 $2,880 - $11,565	-4,500 Reduced 8.59%	47,900 $31,000
Q1 2022 May 16, 2022	SELL	$2.28 - $4.26 $21,431 - $40,044	-9,400 Reduced 15.21%	52,400 $137,000
Q4 2021 Feb 14, 2022	BUY	$3.69 - $6.37 $53,505 - $92,365	14,500 Added 30.66%	61,800 $240,000
Q3 2021 Nov 15, 2021	BUY	$3.25 - $4.66 $35,425 - $50,794	10,900 Added 29.95%	47,300 $206,000
Q2 2021 Aug 16, 2021	BUY	$3.29 - $5.21 $82,908 - $131,292	25,200 Added 225.0%	36,400 $145,000
Q1 2021 May 17, 2021	BUY	$4.17 - $6.73 $46,704 - $75,376	11,200 New	11,200 $58,000
Q4 2020 Feb 16, 2021	SELL	$4.65 - $7.79 $81,375 - $136,325	-17,500 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$4.12 - $9.09 $25,956 - $57,267	-6,300 Reduced 26.47%	17,500 $85,000
Q2 2020 Aug 14, 2020	BUY	$1.84 - $6.44 $11,960 - $41,860	6,500 Added 37.57%	23,800 $116,000
Q1 2020 May 15, 2020	BUY	$1.54 - $6.75 $9,702 - $42,525	6,300 Added 57.27%	17,300 $38,000
Q4 2019 Feb 14, 2020	BUY	$3.06 - $8.78 $33,660 - $96,580	11,000 New	11,000 $64,000

Others Institutions Holding AQST

# of Institutions

127

Shares Held

47.4M

Call Options Held

64.2K

Put Options Held

204K

View Full List

About Aquestive Therapeutics, Inc.

Ticker AQST
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,350,700
Market Cap $376M
Description
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...

More about AQST

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account